Regulation And Legal
Merck Pembrolizumab Granted Orphan Status
FDA granted orphan drug designation to Merck's pembrolizumab (Keytruda) for neuroendocrine prostate cancer on June 6, 2026.
Orphan status offers incentives including seven-year market exclusivity for
